Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Low Dose Thoracic Radiotherapy for ES-SCLC
NCT03532880Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2018
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in small cell lung cancer (SCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose at 1 year and Safety of olaparib in combination with low dose thoracic radiotherapy at 1 year. Started Jul 2018; status: completed.
02
Drugs
olaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03532880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532880.